Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 186 posts found.

roche__tree

Roche’s Tecentriq combo extends life in untreated lung cancer

June 25, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer, pharma, tecentriq

Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

June 22, 2018
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …

News
opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

News
roche

Roche’s breast, lung cancer offerings fail to impress at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

News

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

News

AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer

May 25, 2018
Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

News
astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

News
merckwindow_web

Keytruda success continues, beating Opdivo in lung cancer survival

April 17, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

News
shutterstock_79370437

Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso

April 13, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …

News
msd

Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression

April 10, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

News
roche_glass_building

Tecentriq third time lucky after NICE nod in lung cancer

April 9, 2018
Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …

News
credit_ut_southwestern

Twin-drug combo effectively shrinks lung cancers by blocking their “escape route”

April 4, 2018
Research and Development Cancer, epidermal growth factor, lung cancer, pharma, tumour necrosis factor

A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …

News
roche_close

Roche’s Tecentriq improves OS in first-line lung cancer

March 26, 2018
Research and Development, Sales and Marketing Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News
pfizer-building-logo1web

Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer

January 19, 2018
Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023